This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JUNS Jupiter Neurosciences (JUNS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesInsider TradesTrendsBuy This Stock About Jupiter Neurosciences Stock (NASDAQ:JUNS) 30 days 90 days 365 days Advanced Chart Get Jupiter Neurosciences alerts:Sign Up Key Stats Today's Range$1.30▼$1.4250-Day Range N/A52-Week Range N/AVolume93,016 shsAverage Volume440,410 shsMarket Capitalization$45.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company Overview Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida. Read More Receive JUNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jupiter Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address JUNS Stock News HeadlinesJupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted ScienceJuly 23, 2025 | globenewswire.comJupiter Neurosciences, Inc.: Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 12, 2025 | finanznachrichten.deOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.August 2 at 2:00 AM | InvestorPlace (Ad)Jupiter Neurosciences approves executive bonus package with stock ...July 11, 2025 | investing.comJupiter Neurosciences Regains Nasdaq Compliance July 2025July 11, 2025 | msn.comJupiter Neurosciences, Inc. Regains Nasdaq Compliance as Stock Price Shows Positive MomentumJuly 10, 2025 | quiverquant.comQJupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 10, 2025 | globenewswire.comJupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery - MorningstarJuly 2, 2025 | morningstar.comMSee More Headlines JUNS Stock Analysis - Frequently Asked Questions How were Jupiter Neurosciences' earnings last quarter? Jupiter Neurosciences, Inc. (NASDAQ:JUNS) posted its earnings results on Thursday, May, 15th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.02. When did Jupiter Neurosciences IPO? Jupiter Neurosciences (JUNS) raised $11 million in an initial public offering on Tuesday, December 3rd 2024. The company issued 2,800,000 shares at $4.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO. Company Calendar Last Earnings5/15/2025Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolNASDAQ:JUNS CIK1679628 Webwww.jupiterorphan.com Phone561 406 6154FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.91 Quick Ratio1.91 Sales & Book Value Annual Sales$230 thousand Price / Sales195.72 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book10.46Miscellaneous Outstanding Shares33,100,000Free FloatN/AMarket Cap$45.02 million OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:JUNS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.